RxDoctor Payments Data

Yulia Okhotina, MD

Internal Medicine · Wyomissing, PANPI 1538305560

Payments from drug & device makers

$1,643in general payments, 2019–2025

Across 27 payments — averaging $60.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$349
  • Lilly USA, LLC$297
  • Optinose US, Inc.$203
  • Intra-sana Laboratories$160
  • Amgen$121
  • Biohaven Pharmaceutical Holding Company Ltd.$117
  • plus $396 from 7 others

What the payments were for

  • Food & beverage$1,643100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,643 in reported general payments places this provider in the 80th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$64,198
Medicare patients
198
Services billed
659

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban17$23,888
TrulicityDulaglutide12$15,474
FarxigaDapagliflozin Propanediol12$14,846
JanuviaSitagliptin Phosphate22$11,092
Doxepin Hcl14$4,223
Lidocaine22$2,665
Diclofenac Sodium21$1,783
Rosuvastatin Calcium98$862
Levothyroxine Sodium82$835
Amlodipine Besylate129$805
SynthroidLevothyroxine Sodium22$784
Atorvastatin Calcium123$774
Duloxetine Hcl27$750
Bupropion XlBupropion Hcl12$568
Metoprolol Succinate26$518

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$297$15,47412 claims
AstraZenecaFarxiga$116$14,84612 claims
MerckJanuvia$17$11,09222 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Wyomissing

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →